JonesTrading analyst Sean Kim PhD maintained a Hold rating on Arcutis Biotherapeutics (ARQT – Research Report) today. The company’s shares closed today at $10.63.
According to TipRanks, Kim PhD is a 5-star analyst with an average return of 36.1% and a 52.63% success rate. Kim PhD covers the Healthcare sector, focusing on stocks such as CymaBay Therapeutics, Arcutis Biotherapeutics, and EyePoint Pharmaceuticals.
Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.80.
See the top stocks recommended by analysts >>
ARQT market cap is currently $937M and has a P/E ratio of -1.71.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARQT in relation to earlier this year. Most recently, in December 2023, Todd Franklin Watanabe, the Reporting Person’s title: President and CEO of ARQT bought 59,525.00 shares for a total of $100,002.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcutis Biotherapeutics (ARQT) Company Description:
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Read More on ARQT:
- Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Arcutis Biotherapeutics price target raised to $16 from $8 at Mizuho
- Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
- Arcutis Biotherapeutics Launches Stock Option Exchange Program
- Arcutis Biotherapeutics Inc (ARQT) Q4 Earnings Cheat Sheet
